Skip to main content
SpringerLink
Log in

Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Severe infectious complications reflect a continuing problem in patients with acute myeloid leukemia (AML). Based on data from a randomized clinical trial demonstrating a reduction of proven and probable invasive fungal disease (IFD), posaconazole has been approved for prophylaxis of fungal infections in AML patients during induction chemotherapy. Nevertheless, recently published observational studies show contradictory results concerning the efficacy of posaconazole in this clinical setting. Furthermore, oral suspension posaconazole is associated with an unpredictable bioavailability that especially depends on nutritional factors or gastric pH value.

Patients and methods

We retrospectively analyzed the impact of posaconazole prophylaxis in 70 consecutively evaluable AML patients who underwent induction chemotherapy at a tertiary care hospital. The incidence of IFD classified as proven, probable or possible, antifungal therapy including empiric treatment in high-risk patients and tolerability of posaconazole were determined. In addition, important clinical cofactors such as co-treatment with proton pump inhibitors and risk factors for pneumonia were analyzed in this study.

Results

We can demonstrate that posaconazole is well tolerated and had to be stopped in only six patients (8.6 %). The overall incidence of IFD was 30 % including two patients with proven (2.8 %), four patients with probable (5.7 %) and 15 patients with possible IFD (21.4 %). Importantly, 24 out of 49 patients (49.0 %) who did not fulfill the criteria of IFD received empiric antifungal therapy. Including patients classified as possible IFD, 39 of 70 patients (55.7 %) underwent at least first-line antifungal treatment.

Conclusion

Our “real-life” data obtained from 70 AML patients after induction chemotherapy demonstrate the frequent necessity of systemic antifungal treatment despite prophylaxis with oral suspension posaconazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dolken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Ponisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D (2009) Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 23:635–640

    Article  CAS  PubMed  Google Scholar 

  • Becker C, Ali HA, Krahl R, Poenisch W, Wedding U, Fiedler F, Pasold R, Freund M, Subert R, Kaempfe D, Meran J, Herold M, Peter N, Knauf W, Kettner E, Schultze W, Dachselt K, Wolf HH, Kreibich U, Schulze M, Ittel T, Assmann M, Grobe N, Huhn R, Steglich J, Schirmer V, Klinkenstein C, Opitz B, Winkelmann C, Haak U, Helbig W, Niederwieser D (2004) High complete remission rate in patients with acute myeloid leukemia (AML) above the age of 60 years: a report of the AML97#38 study of the East German Hematology and Oncology Study Group. ASH annual meeting Abstracts 104: 880

  • Bertz H, Drognitz K, Lubbert M (2014) No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year “real-life” evaluation. Ann Hematol 93:165–167

    Article  PubMed  Google Scholar 

  • Bourdelin M, Grenouillet F, Daguindau E, Muret P, Desbrosses Y, Dubut J, Deconinck E, Limat S, Larosa F (2014) Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice. Med Mycol 52:728–735

    Article  PubMed  Google Scholar 

  • Brothman AR, Persons DL, Shaffer LG (2009) Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 127:1–4

    Article  CAS  PubMed  Google Scholar 

  • Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359

    Article  CAS  PubMed  Google Scholar 

  • De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821

    Article  PubMed Central  PubMed  Google Scholar 

  • Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474

    Article  PubMed  Google Scholar 

  • Duarte RF, Lopez-Jimenez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H (2014a) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58:5758–5765

    Article  PubMed Central  PubMed  Google Scholar 

  • Duarte RF, Sanchez-Ortega I, Cuesta I, Arnan M, Patino B, Fernandez de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M (2014b) Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 59:1696–1702

    Article  PubMed  Google Scholar 

  • Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, Ost DE (2013) Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc 10:432–440

    Article  PubMed Central  PubMed  Google Scholar 

  • Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Matturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foa R, Micozzi A (2012) Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 97:560–567

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S (2010) Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 27:1037–1045

    Article  PubMed  Google Scholar 

  • Heussel CP, Kauczor HU, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M (1999) Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 17:796–805

    CAS  PubMed  Google Scholar 

  • Krishna G, Moton A, Ma L, Medlock MM, McLeod J (2009) Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958–966

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kung HC, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR (2014) Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. Cancer Med 3:667–673

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R, Bretagne S, Bergeron A, Azoulay E, Molina JM, Lafaurie M (2014) Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect 20(11):952–959

    Article  Google Scholar 

  • Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN (2014) Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 58:3610–3617

    Article  PubMed Central  PubMed  Google Scholar 

  • Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26(1):21–33

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, Nicolini FE, Labussiere H, Ducastelle S, Barraco F, Thomas X, Chelghoum Y, Nicolle MC, Bienvenu AL, Persat F, De Monbrison F, Picot S, Vanhems P (2012) Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis 31:991–997

    Article  CAS  PubMed  Google Scholar 

  • Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M (2013) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 92:433–442

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075

    PubMed  Google Scholar 

  • Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A (2010) Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95:644–650

    Article  PubMed Central  PubMed  Google Scholar 

  • Pagano L, Verga L, Busca A, Martino B, Mitra ME, Fanci R, Ballanti S, Picardi M, Castagnola C, Cattaneo C, Nadali G, Nosari A, Candoni A, Caira M, Salutari P, Lessi F, Aversa F, Tumbarello M (2014) Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. J Antimicrob Chemother 69:3142–3147

    Article  CAS  PubMed  Google Scholar 

  • Peterson L, Ostermann J, Rieger H, Ostermann H, Rieger CT (2013) Posaconazole prophylaxis–impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses 56:651–658

    Article  CAS  PubMed  Google Scholar 

  • Ruping MJ, Vehreschild JJ, Cornely OA (2008) Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68:1941–1962

    Article  PubMed  Google Scholar 

  • Sandherr M, Maschmeyer G (2011) Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. Eur J Med Res 16:139–144

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Specchia G, Pastore D, Carluccio P, Mele G, Montagna MT, Liso A, Rizzi R, Ianora AS, Liso V (2003) Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma 44:97–101

    Article  PubMed  Google Scholar 

  • Syrjala H, Ohtonen P, Kinnunen U, Raty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itala-Remes M, Silvennoinen R, Koistinen P (2010) Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29:1211–1218

    Article  CAS  PubMed  Google Scholar 

  • Tacke D, Buchheidt D, Karthaus M, Krause SW, Maschmeyer G, Neumann S, Ostermann H, Penack O, Rieger C, Ruhnke M, Sandherr M, Schweer KE, Ullmann AJ, Cornely OA (2014) Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 93:1449–1456

    Article  CAS  PubMed  Google Scholar 

  • Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II (2005) Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5:775–785

    Article  CAS  PubMed  Google Scholar 

  • Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347

    Article  CAS  PubMed  Google Scholar 

  • Vehreschild JJ, Ruping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA (2010) Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 65:1466–1471

    Article  CAS  PubMed  Google Scholar 

  • Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44:2–12

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the “Förderprogramm Infektiologie 2013” as a grant from Gilead (Munich, Germany).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II (Abteilung Hämatologie und Internistische Onkologie), Universitätsklinikum Jena, Erlanger Allee 101, 07747, Jena, Germany

    Karin G. Schrenk, Ulf Schnetzke, Katy Stegemann, Marie von Lilienfeld-Toal, Andreas Hochhaus & Sebastian Scholl

Authors
  1. Karin G. Schrenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulf Schnetzke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katy Stegemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie von Lilienfeld-Toal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sebastian Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastian Scholl.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schrenk, K.G., Schnetzke, U., Stegemann, K. et al. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J Cancer Res Clin Oncol 141, 1661–1668 (2015). https://doi.org/10.1007/s00432-015-1962-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-1962-x

Keywords

Search

Navigation